Glenmark Pharmaceuticals USA launches Epinephrine Injection USP, multiple-dose vial

According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million

Biocon inks out-licensing agreement with Ajanta to market Semaglutide in 26 countries

Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia

Cupid reduces promoter pledged stake to 20%

This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence

GSK strikes deal with US to lower prescription drug costs & boost respiratory medicine access

GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%

Emcure Pharma launches weight loss drug Poviztra in India

Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management

GABIT acquires Swedish nutrition brand Nack to build integrated longevity ecosystem

Merck strikes historic deal with Trump admin to lower drug costs for Americans

Qihan Biotech launches first-in-human trial of off-the-shelf CAR-T therapy for refractory lupus

The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation

Briefs: APL Healthcare, Biocon, USFDA, Sun Pharma and Clean Fino-Chem

USFDA determines Sun Pharma's Baska facility inspection classification as OAI

JHS Svendgaard to invest Rs. 25 crore on building new manufacturing unit

The new facility is expected to generate 500-600 new jobs in the region